 |
인쇄하기
취소
|
LG Life Science to export Factive technology
LG Life Science said on October 22 that it signed with GeneSoft, an US bioventure firm, a strategic alliance agreement for the marketing of a novel quinolone antibiotic Factive it developed.
Under the agreement, GeneSoft is to pay US$40.50 million as a technology transfer fee and following the commercialization of the new product with the new technology to be developed by LG Life Science, LG...
Under the agreement, GeneSoft is to pay US$40.50 million as a technology transfer fee and following the commercialization of the new product with the new technology to be developed by LG Life Science, LG...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.